Within the secondary analysis, the a lot less conservative but clinically meaningful criterion of steady response (described for a 50% or more reduction in MADRS from baseline for 2 weeks) was used. With the patients who attained stable reaction, 25.eight% inside the esketamine group and 57.6% while in the placebo https://aeschylusd799ncs7.blogsvirals.com/profile